Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deferred Tax Liability (2021 - 2023)

Aytu Biopharma has reported Non-Current Deferred Tax Liability over the past 4 years, most recently at $100000.0 for Q2 2023.

  • Quarterly Non-Current Deferred Tax Liability changed 0.0% to $100000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Jun 2023, changed 0.0% year-over-year, with the annual reading at $100000.0 for FY2023, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability was $100000.0 for Q2 2023 at Aytu Biopharma, roughly flat from $100000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $200000.0 in Q2 2021 and troughed at $100000.0 in Q3 2021.
  • The 3-year median for Non-Current Deferred Tax Liability is $100000.0 (2021), against an average of $120000.0.
  • Year-over-year, Non-Current Deferred Tax Liability crashed 50.0% in 2022 and then changed 0.0% in 2023.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023.
  • Per Business Quant, the three most recent readings for AYTU's Non-Current Deferred Tax Liability are $100000.0 (Q2 2023), $100000.0 (Q2 2022), and $100000.0 (Q4 2021).